Report: Monoclonal antibodies for dementia lack clear benefits, show risks
By
Kristen Fischer
Jan 23, 2024
Even though amyloid-reducing monoclonal antibodies (MABs) are on the market and some research shows they may treat Alzheimer’s disease and dementia, a new research review found there aren’t clear benefits...
Patient advocates decry CMS decision on Alzheimer’s drug coverage
By
Alicia Lasek
Feb 24, 2023
The Alzheimer’s Association and others have strongly criticized a decision by CMS to stand by its highly restrictive coverage for new dementia drugs.
Amyloid brain plaques not a sure sign of Alzheimer’s, researchers find
By
Alicia Lasek
Jan 12, 2023
A new study challenges the theory that an increase in brain amyloid protein signals Alzheimer’s disease. The findings may be especially relevant to clinicians as amyloid-targeting drugs such as Leqembi...
FDA approves new drug Leqembi to treat early Alzheimer’s disease
By
Alicia Lasek
Jan 09, 2023
The newly approved drug Leqembi (lecanemab) may slow progression of cognitive decline due to Alzheimer’s disease, trial data show. CMS says it may rethink Medicare coverage of drugs in Leqembi’s...
Alzheimer’s drug plus clot buster caused brain hemorrhage death: report
By
Alicia Lasek
Jan 06, 2023
A clot-busting drug administered during a stroke helped lead to the death of a patient taking the experimental Alzheimer’s drug lecanemab, a peer-reviewed autopsy analysis has revealed.